Acucela, Otsuka Enter Deals For Eye Drugs
This article was originally published in PharmAsia News
Executive Summary
Acucela's deal with Otsuka to develop two eye-disorder drugs follows news of the plan by Shionogi to buy out Sciele, pointing up the continued interest from Japanese pharma in U.S. firms
You may also be interested in...
Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug
Seattle-based ophthalmology specialist Acucela has struck its third partnership with Japanese pharma Otsuka Pharmaceutical Co., this time to collaborate on development of a preclinical glaucoma treatment
Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug
Seattle-based ophthalmology specialist Acucela has struck its third partnership with Japanese pharma Otsuka Pharmaceutical Co., this time to collaborate on development of a preclinical glaucoma treatment
Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition
TOKYO - Shionogi moved Sept. 1 to establish a sales presence in the U.S. through the acquisition of Atlanta-based Sciele Pharma. Boards of both firms approved the $1.42 billion purchase, for $31 per share, prior to the announcement